Penicillin-G acylases

US10865402B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10865402-B2
Application numberUS-202016927129-A
CountryUS
Kind codeB2
Filing dateJul 13, 2020
Priority dateJan 5, 2017
Publication dateDec 15, 2020
Grant dateDec 15, 2020

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention provides engineered penicillin G acylase (PGA) enzymes, polynucleotides encoding the enzymes, compositions comprising the enzymes, and methods of using the engineered PGA enzymes.

First claim

Opening claim text (preview).

We claim: 1. An engineered polynucleotide encoding an engineered penicillin G acylase capable of acylating insulin, wherein the polypeptide sequence of said penicillin G acylase is 90% or more identical to SEQ ID NO: 100, and wherein the residue at position X67 as compared to SEQ ID NO: 100 is an alanine. 2. The engineered polynucleotide encoding the engineered penicillin G acylase of claim 1 , wherein said penicillin G acylase comprises a sequence that is at least 90% or more identical to at least one sequence set forth in Table 5.1, 5.2, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 7.1, 8.1, 9.1, 11.1, 12.1, 13.1, 14.1, 15.1, 16.1, 17.1, 18.1, 19.1, 20.1, 22.1, 23.1, and/or 23.2. 3. The engineered polynucleotide encoding the engineered penicillin G acylase of claim 1 , wherein said penicillin G acylase comprises a sequence set forth in Table 5.1, 5.2, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 7.1, 8.1, 9.1, 11.1, 12.1, 13.1, 14.1, 15.1, 16.1, 17.1, 18.1, 19.1, 22.1, 23.1, and/or Table 23.2. 4. The engineered polynucleotide encoding the engineered penicillin G acylase of claim 1 , wherein said engineered penicillin G acylase comprises a polypeptide sequence selected from SEQ ID NOS:100 and 110. 5. The engineered polynucleotide sequence of claim 1 , wherein said sequence comprises a polynucleotide sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to SEQ ID NOS: 1, 11, 23, 39, 55, 69, 81, 99, 107, 109, 115, 135, 141, 153, and/or 159. 6. A vector comprising the polynucleotide sequence of claim 1 . 7. The vector of claim 6 , further comprising at least one control sequence. 8. A host cell comprising the vector of claim 7 . 9. A method for producing acylated insulin, comprising: providing the engineered penicillin G acylase encoded by the polynucleotide of claim 1 and insulin; exposing said engineered penicillin G acylase and said insulin under conditions such that said engineered penicillin G acylase acylates said insulin, thereby producing acylated insulin. 10. The method of claim 9 , wherein said acylation is conducted in the presence of methyl phenylacetate. 11. The method of claim 9 , wherein said acylation occurs at any of positions A1, B1, and/or B29 of said insulin. 12. The method of claim 10 , wherein said acylation occurs at any of positions A1, B1, and/or B29 of said insulin. 13. The method of claim 9 , wherein said acylation occurs at position A1 of said insulin. 14. The method of claim 9 , wherein said acylation occurs at position B1 of said insulin. 15. The method of claim 9 , wherein said acylation occurs at position B29 of said insulin. 16. The method of claim 9 , wherein said engineered penicillin G acylase produces more than 90% more acylated insulin as compared to the production of acylated insulin by the polypeptide of SEQ ID NO: 2, 4, 12, 24, 40, 56, 70, 82, 100, 108, 110, 116, 136, 142, 154 and/or 160.

Assignees

Inventors

Classifications

  • Penicillin amidase (3.5.1.11), i.e. penicillin-amidohydrolase · CPC title

  • Insulins · CPC title

  • having a known sequence of two or more amino acids, e.g. glutathione · CPC title

  • containing a His-tag · CPC title

  • C12N9/84Primary

    Penicillin amidase {(3.5.1.11)} · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10865402B2 cover?
The present invention provides engineered penicillin G acylase (PGA) enzymes, polynucleotides encoding the enzymes, compositions comprising the enzymes, and methods of using the engineered PGA enzymes.
Who is the assignee on this patent?
Codexis Inc
What technology area does this patent fall under?
Primary CPC classification C12N9/84. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Dec 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).